Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

XARELTO 1 MG/ML SUSPENSION

rivaroxaban
$3.7634per ML
High Outlier

Strength

155 mg/1

Manufacturer

Janssen Pharmaceuticals Inc.

NDC

50458057501

Classification

Brand

Dosage Form

GRANULE, FOR SUSPENSION

Route

ORAL

Last Updated

2/3/2026

Active Ingredients

RIVAROXABAN

Approval Type

New Drug (NDA)

FDA Application

NDA215859

On Market Since

12/1/2021

Pharmacological Classes

Factor Xa Inhibitor
Factor Xa Inhibitors

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

+2.2%

1Y

+1.1%

3Y

N/A

5Y

N/A

All

+1.1%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

ELIQUIS 2.5 MG TABLET
Brand
00003089321•E.R. Squibb & Sons, L.L.C.
$5.5232
per EA
ELIQUIS 2.5 MG TABLET
Brand
00003089331•E.R. Squibb & Sons, L.L.C.
$5.5232
per EA
ELIQUIS 5 MG TABLET
Brand
00003089421•E.R. Squibb & Sons, L.L.C.
$5.5265
per EA
ELIQUIS 5 MG TABLET
Brand
00003089431•E.R. Squibb & Sons, L.L.C.
$5.5265
per EA
ELIQUIS 5 MG TABLET
Brand
00003089470•E.R. Squibb & Sons, L.L.C.
$5.5265
per EA
SAVAYSA 60 MG TABLET
Brand
65597020305•Daiichi Sankyo Inc.
$12.4609
per EA
SAVAYSA 60 MG TABLET
Brand
65597020390•Daiichi Sankyo Inc.
$12.4609
per EA
SAVAYSA 30 MG TABLET
Brand
65597020205•Daiichi Sankyo Inc.
$12.4819
per EA
SAVAYSA 30 MG TABLET
Brand
65597020290•Daiichi Sankyo Inc.
$12.4819
per EA
SAVAYSA 30 MG TABLET
Brand
65597020230•Daiichi Sankyo Inc.
$14.5678
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy